Physician profile
Arthur W Pearson
NPI 1811331754
$3,293.37
in general payments reported to CMS, 2019-2025
30 companies · $261 in 2025
The $261 reported for 2025 was more than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $781 · 2020: $601 · 2021: $290 · 2022: $380 · 2023: $526 · 2024: $455 · 2025: $261.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,203 · Education: $38.54.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,203.45 |
| Education | $38.54 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $542.87 | 2019-2025 | Farxiga, Airsupra, Lokelma |
| Sanofi-Aventis U.S. LLC | $528.23 | 2019-2023 | |
| Novo Nordisk INC | $386.85 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Boehringer Ingelheim Pharmaceuticals, INC. | $266.52 | 2019-2024 | Jardiance |
| Glaxosmithkline, LLC. | $233.02 | 2020-2025 | Trelegy Ellipta, Arexvy |
| Pfizer INC. | $147.21 | 2019-2024 | |
| Lilly USA, LLC | $135.67 | 2020-2025 | Mounjaro, Zepbound, Jardiance |
| Exact Sciences Corporation | $110.41 | 2023-2024 | Cologuard Collection Kit |
| Janssen Pharmaceuticals, INC | $108.48 | 2022-2024 | Xarelto |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $86.17 | 2019-2022 | |
| Lundbeck LLC | $84.26 | 2024-2025 | Rexulti |
| Merck Sharp & Dohme LLC | $77.31 | 2019-2023 | Vaxneuvance, M-M-R II, Vaxelis |
| Bayer Healthcare Pharmaceuticals INC. | $71.25 | 2022-2024 | |
| Abbvie INC. | $67.42 | 2021-2023 | |
| Allergan, INC. | $53.04 | 2020 |
Show all 30 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Biohaven Pharmaceutical Holding Company LTD. | $40.16 | 2022 | |
| Sumitomo Pharma America, INC. | $39.24 | 2023 | Gemtesa |
| Mylan Specialty L.P. | $38.58 | 2020-2021 | |
| Amgen INC. | $38.44 | 2019 | |
| Otsuka America Pharmaceutical, INC. | $33.08 | 2025 | Rexulti |
| Amarin Pharma, INC. | $32.52 | 2020 | |
| Xeris Pharmaceuticals, INC. | $31.55 | 2022 | |
| Vanda Pharmaceuticals INC. | $22.34 | 2025 | Fanapt |
| Dexcom, INC. | $20.23 | 2025 | Dexcom G6 Transmitter |
| Ultragenyx Pharmaceutical INC. | $19.71 | 2021 | |
| Astellas Pharma US INC | $18.49 | 2020 | |
| Viatris Specialty LLC | $17.09 | 2025 | Yupelri |
| Eisai INC. | $15.15 | 2021 | |
| Kowa Pharmaceuticals America, INC. | $14.58 | 2021 | |
| Novartis Pharmaceuticals Corporation | $13.50 | 2023 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Arthur Pearson listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.